Beijing Hongtianji Neuroscience Academy, Beijing, People Republic of China; Institute of Neurorestoratology, Third Medical Center of General Hospital of PLA, Beijing, People Republic of China.
Beijing Hongtianji Neuroscience Academy, Beijing, People Republic of China.
Prog Brain Res. 2021;265:231-247. doi: 10.1016/bs.pbr.2021.06.006. Epub 2021 Aug 13.
Clinical neurorestorative cell therapies for stroke have been explored for over 20 years. Majority cell therapies have shown neurorestorative effects for stroke on non-double-blind studies. In this review, we summarize types of cell transplantation, transplanted routes, therapeutic time windows, dosage, results of exploring trials or clinical studies, results of multicenter, double-blind or observing-blind, randomized, placebo-controlled clinical trials. The clinical application prospects of majority cell therapies for stroke need to prove their neurorestorative effects through trials with higher-level evidence-based medical evidence. Currently olfactory ensheathing cell is only one kind of cell to show neurorestorative effects through multicenter, double-blind, randomized, placebo-controlled clinical trials, which should be explored to optimize themselves effects and combination with others.
临床神经修复细胞疗法治疗中风已经探索了 20 多年。大多数细胞疗法在非双盲研究中显示对中风有神经修复作用。在这篇综述中，我们总结了细胞移植的类型、移植途径、治疗时间窗、剂量、探索性试验或临床研究的结果、多中心、双盲或观察性盲、随机、安慰剂对照临床试验的结果。大多数细胞疗法治疗中风的临床应用前景需要通过更高水平的循证医学证据的试验来证明其神经修复作用。目前，嗅鞘细胞是唯一一种通过多中心、双盲、随机、安慰剂对照临床试验显示神经修复作用的细胞，应该进一步探索以优化其自身作用，并与其他细胞联合应用。
